EMERGENCY:Sudden severe memory deterioration, new aphasia, or acute confusion — this may indicate a stroke —call040-46324365immediately — 24 hours, 7 days— 24/7
Mild cognitive impairment (MCI) is the clinical state between normal age-related cognitive change and dementia: the person has measurable decline in one or more cognitive domains — memory, attention, executive function, language, or visuospatial ability — that exceeds what is expected for their age and education level, but has not yet impaired their ability to manage daily activities independently. The concept of MCI is important because it identifies a high-risk population at the stage when intervention may still meaningfully alter the trajectory — before the disability of dementia has developed.
MCI is the clinical state between normal age-related cognitive change and dementia: the person has measurable decline in one or more cognitive domains (memory, attention, executive function, language, or visuospatial ability) that exceeds what is expected for their age and education, but has not yet impaired independent daily activities. Four criteria: (1) subjective cognitive complaint; (2) objective impairment >1.5 SD below age/education norms on at least one domain; (3) preserved general cognitive function; (4) largely preserved functional independence. Amnestic MCI (aMCI): memory predominantly affected — highest risk of conversion to Alzheimer's disease, 10-15% per year. Non-amnestic MCI: predicts other dementia types (attention + visuospatial = Lewy body; executive + language = FTD; executive + processing speed = vascular). Reversible causes that must be excluded first: depression, hypothyroidism, B12 deficiency, sleep apnoea, medications, uncontrolled diabetes or hypertension. Assessment at KIMS: MoCA (sensitivity ~90% vs MMSE ~50%), NIMHANS Neuropsychological Battery, MRI with hippocampal volumetry, blood biomarkers. Management: aggressive vascular risk factor control (SPRINT-MIND: intensive BP control reduced MCI incidence by 19%); aerobic exercise (most evidence-based non-pharmacological intervention); treat hearing loss; no cholinesterase inhibitors (insufficient evidence).
| Fact | Details |
|---|---|
| Prevalence | 7-10% of Indians over 60 · Increases steeply with age: 15-20% over 75 · Annual conversion 10-15% to dementia (not inevitable; 30-40% stable over 5 years) |
| MoCA vs MMSE | MoCA sensitivity ~90% for MCI · MMSE sensitivity ~50% for MCI · Always use MoCA (validated in Hindi and Telugu) · Score <26 = probable MCI |
| Reversible causes (exclude first) | Depression (most common India) · Hypothyroidism (TSH) · B12 deficiency (common in vegetarian elderly; check MMA + homocysteine) · OSA · Anticholinergic/benzo medications · Uncontrolled HTN/diabetes |
| Strongest pharmacological intervention | SPRINT-MIND: intensive BP control <130/80 mmHg reduced MCI incidence 19% · HbA1c control · Statin for dyslipidaemia · Smoking cessation |
| Strongest lifestyle intervention | Aerobic exercise: 150 min/week moderate-intensity · Increases hippocampal volume + improves memory scores · Also: treat hearing loss (largest modifiable dementia risk factor) · Sleep 7-8 hours (amyloid clearance via glymphatic system) |
| Medications NOT recommended | Cholinesterase inhibitors (donepezil, rivastigmine): NOT recommended for MCI · Large trials negative for significant benefit · No FDA or EMA approval for MCI |
| Annual monitoring at KIMS | Repeat MoCA annually · Extended neuropsychological battery every 1-2 years · Functional assessment (any ADL impairment = transition to dementia) · Repeat MRI at 2-3 years for hippocampal volume change |
7–10% of Indians over 60 · Increases steeply with age: 15–20% over 75.
Amnestic MCI (aMCI): memory predominantly affected · Non-amnestic MCI: other domains (attention, executive, language, visuospatial) predominantly affected · Single-domain vs multi-domain.
Approximately 10–15% per year convert to Alzheimer's or other dementia · Not inevitable: some MCI is stable · Some revert to normal with treated reversible causes.
Depression · Hypothyroidism · B12 deficiency · Sleep apnoea · Medication side effects · Poorly controlled diabetes or hypertension · Must be excluded before MCI diagnosis.
Age · APOE ε4 genotype · MRI hippocampal atrophy · Amyloid PET positive · Low CSF Aβ42:tau ratio · Hypertension + diabetes + cardiovascular disease.
Physical exercise (most robustly protective) · Cognitive engagement · Social engagement · Hearing aid use (if hearing-impaired) · Adequate sleep · Diet (Mediterranean pattern).
No approved disease-modifying drug for MCI · Cholinesterase inhibitors not routinely recommended for MCI (insufficient evidence) · Treat all vascular risk factors aggressively.
"Normal ageing" explanation prevalent · Late presentation · Hindi and Telugu validated MoCA versions available at KIMS · Literacy-adjusted cognitive testing important.
Mild cognitive impairment (MCI) is the clinical state between normal age-related cognitive change and dementia: the person has measurable decline in one or more cognitive domains — memory, attention, executive function, language, or visuospatial ability — that exceeds what is expected for their age and education level, but has not yet impaired their ability to manage daily activities independently. The concept of MCI is important because it identifies a high-risk population at the stage when intervention may still meaningfully alter the trajectory — before the disability of dementia has developed.
In India, MCI is substantially underdiagnosed. Most families attribute memory decline in older relatives to normal ageing ("it is just old age") without seeking assessment. The KIMS memory clinic provides comprehensive cognitive evaluation — using neuropsychological testing, MRI brain with hippocampal volumetry, blood biomarkers, and risk factor assessment — to distinguish normal ageing from MCI, and MCI from early dementia. The distinction matters because the treatment approach, the prognosis, and the family planning implications are different at each stage.
Speak directly with the KIMS memory clinic team — all coordinated under one roof for MoCA-based cognitive assessment, hippocampal MRI, reversible cause work-up, and annual monitoring.
040-44885000Memory clinic consultation lineFour foundational principles that shape how MCI is distinguished from normal ageing and early dementia at KIMS
Normal ageing produces modest, predictable changes in cognition: slower processing speed (taking longer to react, think, and respond) · Mild word-finding difficulty (tip-of-the-tongue experiences that resolve) · Slightly reduced ability to hold multiple items in working memory simultaneously · Increased susceptibility to distraction. Crucially, normal ageing does not produce: forgetting entire conversations · Getting lost in familiar places · Losing the ability to manage finances · Forgetting the names of close family members · Making repeatedly poor judgements. Any of these latter features suggests MCI or dementia rather than normal ageing.
MCI requires four criteria: (1) Subjective cognitive complaint — from the person, a family member, or the clinician observing a change. (2) Objective cognitive impairment on standardised testing — performance >1.5 standard deviations below age and education norms on at least one cognitive domain. (3) Preserved general cognitive function — the person is not globally demented; most abilities are intact. (4) Largely preserved functional independence — the person manages day-to-day activities (cooking, finances, transport, medications) without significant assistance.
Amnestic MCI (aMCI) — where memory is the predominantly affected domain — is the most common subtype and carries the highest risk of conversion to Alzheimer's disease. Non-amnestic MCI — where attention, executive function, language, or visuospatial ability is predominantly affected while memory is relatively spared — may predict conversion to other dementia types: Lewy body dementia (attention + visuospatial MCI), frontotemporal dementia (executive function + language MCI), or vascular dementia (executive function + processing speed MCI from white matter disease). Identifying the non-amnestic pattern correctly guides both the diagnostic workup and the family counselling.
Before diagnosing MCI, KIMS excludes conditions that produce a cognitive picture that mimics MCI but is fully reversible: depression (pseudo-dementia — the commonest mimicker in the Indian elderly population) · Hypothyroidism (TSH is always checked) · Vitamin B12 deficiency (very common in vegetarian elderly Indians — MMA + homocysteine for subclinical deficiency) · Obstructive sleep apnoea (causing daytime cognitive slowing — ask the partner) · Medication side effects (anticholinergics, benzodiazepines, antiepileptics, antihistamines, antihypertensives — review the medication list) · Uncontrolled diabetes with chronic hypoglycaemic episodes · Uncontrolled hypertension with cerebrovascular disease.
150 minutes/week of moderate-intensity aerobic exercise (brisk walking) reduces hippocampal atrophy and improves cognitive scores in MCI · The most robust non-pharmacological intervention.
New learning activities, reading, puzzles, social interaction · Use-it-or-lose-it principle.
Mediterranean or MIND diet (combined Mediterranean and DASH) associated with slower cognitive decline.
7–8 hours regular sleep · Treat OSA · Sleep is the period for amyloid clearance via the glymphatic system.
For those with hearing loss — reduces cognitive load and social isolation.
MCI is evaluated at the KIMS memory clinic through a structured four-stage workflow that begins with MoCA-based cognitive screening (validated in Hindi and Telugu) mood risk factors relevant to dementia prevention :
Montreal Cognitive Assessment (MoCA, validated in Hindi and Telugu): 30-point test covering memory, attention, language, executive function, and visuospatial ability in approximately 10 minutes · Sensitivity for MCI ∼90% (vs MMSE ∼50%) · Score <26 = fail. Extended neuropsychological battery (NIMHANS battery or equivalent): detailed testing of each cognitive domain with age and education-corrected norms · Characterises the specific pattern of impairment (which domains, how severe) · Provides a baseline for monitoring.
Standard MRI sequences (T1, T2, FLAIR, DWI) · Medial temporal lobe assessment: hippocampal volumetry (automated or visual Scheltens scale) · White matter hyperintensity burden (Fazekas scale) for vascular contribution · FDG-PET where available: hypometabolism in posterior temporal-parietal regions predicts conversion to Alzheimer's · Amyloid PET (where available): detects amyloid deposits before clinical dementia onset.
TSH (thyroid function) · Vitamin B12 + folate (+ MMA if borderline) · Full blood count (anaemia) · Fasting glucose + HbA1c · Lipid profile · Liver and renal function · Calcium · Serum homocysteine (elevated = independent risk factor for dementia and vascular cognitive impairment) · RPR/VDRL (syphilis — a treatable cause) · HIV (in relevant risk groups).
Cardiovascular risk: blood pressure, BMI, physical activity, smoking, alcohol · Sleep assessment: OSA screening (STOP-BANG questionnaire, polysomnography if positive) · Hearing assessment (hearing loss is the largest modifiable risk factor for dementia in the Lancet 2020 Commission) · Social engagement and depression screening (GDS-15).
The KIMS MCI programme is built around four integrated care areas and functional assessment.
Vascular Risk Factor Control — The Most Important Intervention: Aggressive management of all modifiable vascular risk factors is the most evidence-based intervention for slowing MCI progression: blood pressure target <130/80 mmHg (SPRINT-MIND trial: intensive BP control reduced MCI incidence by 19%) · HbA1c target <7.5% in diabetes · Statin therapy for dyslipidaemia · Smoking cessation · Alcohol moderation · OSA treatment with CPAP.
Lifestyle Interventions — Exercise Is the Strongest: Aerobic exercise: 150 minutes/week of moderate-intensity aerobic exercise (brisk walking) reduces hippocampal atrophy and improves cognitive scores in MCI · The most robust non-pharmacological intervention. Cognitive engagement: New learning activities, reading, puzzles, social interaction · Use-it-or-lose-it principle. Diet: Mediterranean or MIND diet (combined Mediterranean and DASH) associated with slower cognitive decline. Sleep: 7–8 hours regular sleep · Treat OSA · Sleep is the period for amyloid clearance via the glymphatic system. Hearing aids: For those with hearing loss — reduces cognitive load and social isolation.
Pharmacotherapy: No drug is currently approved for MCI. Cholinesterase inhibitors (donepezil, rivastigmine) are NOT recommended for MCI — trials have not shown significant benefit. Treat depression with SSRIs if present (both for mood and for the independent cognitive benefits of treating depression). B12 replacement if deficient. Homocysteine lowering with B-vitamins (B6, B12, folate) — may slow brain atrophy in aMCI with elevated homocysteine.
Monitoring — Annual Review at KIMS Memory Clinic: Repeat MoCA annually · Repeat extended neuropsychological battery every 1–2 years · Review functional status (any new functional impairment = transition to dementia diagnosis) · Repeat MRI at 2–3 years to monitor hippocampal volume change · Family counselling about dementia risk and planning.
A family that has been told 'it is just ageing' for two years. A mother who repeats herself but still manages the house. A father whose memory is falling but who still drives. MCI is the stage at which a formal assessment changes the trajectory.
At KIMS Hyderabad, the memory clinic provides the full evaluation. Call 040-44885000.
International enquiries: info@kimsneurosciences.com